CNR1 and Insulin resistance: Although subsequent studies reported that CNS-specific Cnr1 deficiency alone prevented HFD-induced hepatic steatosis, insulin resistance, and dyslipidemia (42, 43), recent data indicate that peripherally restricted Cnr1 antagonists can indeed prevent this metabolic syndrome (47).